This saves patients hours annually, time they can spend with family, at work, or relaxing, while also offering major ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

The UK's National Health Service has introduced a quick injection method for administering the cancer drug Nivolumab, significantly reducing treatment time and hospital stays.

A new pilot clinical study will explore the safety and effectiveness of 2 anti-canine monoclonal antibodies on solid tumors ...